211 related articles for article (PubMed ID: 28745238)
21. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
[TBL] [Abstract][Full Text] [Related]
22. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
[TBL] [Abstract][Full Text] [Related]
23. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
24. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
25. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
[TBL] [Abstract][Full Text] [Related]
26. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
27. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach.
Vugts DJ; Vervoort A; Stigter-van Walsum M; Visser GW; Robillard MS; Versteegen RM; Vulders RC; Herscheid JK; van Dongen GA
Bioconjug Chem; 2011 Oct; 22(10):2072-81. PubMed ID: 21854058
[TBL] [Abstract][Full Text] [Related]
29. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
[TBL] [Abstract][Full Text] [Related]
30. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
Wojdowska W; Karczmarczyk U; Maurin M; Garnuszek P; Mikołajczak R
Curr Radiopharm; 2015; 8(1):62-8. PubMed ID: 25506704
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent.
Gali H; Hoffman TJ; Sieckman GL; Owen NK; Katti KV; Volkert WA
Bioconjug Chem; 2001; 12(3):354-63. PubMed ID: 11353532
[TBL] [Abstract][Full Text] [Related]
32. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
Grünberg J; Jeger S; Sarko D; Dennler P; Zimmermann K; Mier W; Schibli R
PLoS One; 2013; 8(4):e60350. PubMed ID: 23565233
[TBL] [Abstract][Full Text] [Related]
33. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
34. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
[TBL] [Abstract][Full Text] [Related]
35. The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab.
Novy Z; Laznickova A; Mandikova J; Barta P; Laznicek M; Trejtnar F
J Labelled Comp Radiopharm; 2014 Jun; 57(7):448-52. PubMed ID: 24889367
[TBL] [Abstract][Full Text] [Related]
36. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
37. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
38. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ; Salouti M
Nucl Med Biol; 2009 May; 36(4):363-9. PubMed ID: 19423003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
